Hormonal Effects on Tc-99m Sestamibi Uptake in the Breast
NCT00943527 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 110
Last updated 2012-01-25
Summary
This study is to examine the effects of menstrual cycle, hormone therapy, and the use of tamoxifen on Tc-99m sestamibi uptake.
Conditions
Sponsors & Collaborators
- lead OTHER
-
Gamma Medica-Ideas
collaborator INDUSTRY
Eligibility
- Min Age
- 35 Years
- Max Age
- 45 Years
- Sex
- FEMALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2008-01-31
- Primary Completion
- 2010-12-31
- Completion
- 2012-01-31
Countries
- United States
Study Locations
More Related Trials
-
Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer
NCT00066690 ·Status: COMPLETED ·Phase: PHASE3
-
Tamoxifen Resistance in Women With Stage I, Stage II, Stage IIIA, or Stage IIIB Breast Cancer
NCT00899197 ·Status: TERMINATED
-
Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen
NCT00764322 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Bone Mineral Density in Women With Breast Cancer Treated With Triptorelin and Tamoxifen or Exemestane on Protocol IBCSG 25-02
NCT00963417 ·Status: COMPLETED ·Phase: NA
-
Breast Cancer & Antiestrogenic Therapy & Brain
NCT06346457 ·Status: NOT_YET_RECRUITING
-
Tamoxifen in Treating Women With High-Risk Breast Cancer
NCT00002542 ·Status: COMPLETED ·Phase: PHASE3
-
Changes in Breast Density and Blood Hormone Levels in Postmenopausal Women Receiving Anastrozole or Exemestane for Breast Cancer
NCT00516698 ·Status: COMPLETED
-
Effect of 4-Hydroxytamoxifen Gel on Breast Density, Salivary Sex Steroids, and Quality of Life in Premenopausal Women
NCT00084344 ·Status: COMPLETED ·Phase: NA
-
Trial of Low Dose Tamoxifen in Women With Breast Intraepithelial Neoplasia - Long Term Follow-up
NCT01357772 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer Risk
NCT04570956 ·Status: TERMINATED ·Phase: PHASE2
-
Hormone Therapy in Treating Postmenopausal Women With Receptor-Positive Breast Cancer
NCT00002646 ·Status: COMPLETED ·Phase: PHASE3
-
Radiologic Evaluation and Breast Density (READ)
NCT00117663 ·Status: COMPLETED ·Phase: NA
-
Testing Low Dose Tamoxifen for Invasive Breast Cancer, the (LoTam) Trial
NCT06671912 ·Status: SUSPENDED ·Phase: PHASE3
-
SWOG-8814 Tamoxifen With or Without Combination Chemotherapy in Postmenopausal Women Who Have Undergone Surgery for Breast Cancer
NCT00929591 ·Status: COMPLETED ·Phase: PHASE3
-
Tamoxifen Following Combination Chemotherapy in Treating Women With Operable Invasive Breast Cancer
NCT00002579 ·Status: COMPLETED ·Phase: PHASE3
-
Breath Test for Women Receiving Tamoxifen in the Prevention or Treatment of Breast Cancer
NCT00873366 ·Status: TERMINATED
-
Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction
NCT06195306 ·Status: RECRUITING ·Phase: PHASE2
-
Tamoxifen With or Without Octreotide in Treating Postmenopausal Women With Stage I, Stage II, or Stage III Breast Cancer
NCT00002864 ·Status: COMPLETED ·Phase: PHASE3
-
Examining the Relationships Between Sleep, Fatigue, and Pain in Aromatase Inhibitor-treated Patients
NCT01983995 ·Status: COMPLETED
-
Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer
NCT03351062 ·Status: RECRUITING ·Phase: PHASE3
-
Effect of Tamoxifen on Breast Density in Premenopausal Women With Breast Cancer or High Risk for Breast Cancer
NCT00086749 ·Status: COMPLETED
-
Breast Density, Hormone Levels, and Anticancer Drug Levels in Women With Invasive Breast Cancer Who Are Receiving Exemestane or Anastrozole
NCT00316836 ·Status: COMPLETED
-
Tamoxifen in Treating Women With Breast Cancer
NCT00003678 ·Status: UNKNOWN ·Phase: PHASE3
-
Circulating miRNAs as Biomarkers of Hormone Sensitivity in Breast Cancer
NCT01612871 ·Status: COMPLETED ·Phase: PHASE4
-
Uterine Cavity Assessment and Endometrial Gene Expression in Tamoxifen Treated Breast Cancer Patients
NCT02311647 ·Status: UNKNOWN